Table 3. Clinical characteristics and other relevant information of all AMR cases of leprosy.
| Province | Case type | Sex | Age | WHO | Previous treatment history | R-J | Nerve | Deformity | Reaction | BI at diagnosis | BI at RFT | BI at1 year post RFT | Mutation results | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nth (DNA repair) | folP1 (Dapsone) | rpoA (Rifampicin) | rpoB (Rifampicin) | rpoC (Rifampicin) | gyrA (Ofloxacin) | gyrB (Ofloxacin) | 23s rRNA (Clarithromycin) | |||||||||||||
| Hunan | New | M | 47 | MB | – | BL | Y | Y | N | 3.4 | 2.8 | 2.4 | – | 55; CCC-TCC (Pro-Ser) | – | – | – | – | – | – |
| Hunan | New | M | 37 | MB | – | BL | Y | Y | Y | 3.2 | 2.5 | 1.5 | – | 53; ACC-AGA (Thr -Arg) | – | – | – | – | – | – |
| Hunan | New | M | 30 | MB | – | BL | Y | N | N | 5.2 | 4 | 3 | – | 53; ACC-ATC (Thr-Ile) | – | – | – | – | – | – |
| Guizhou | New | M | 38 | MB | – | LL | N | N | N | 5.4 | 2.8 | 2.2 | – | 55; CCC-TCC (Pro-Ser) | – | – | – | – | – | – |
| Guizhou | New | M | 41 | MB | – | BL | Y | N | N | 1.5 | 3.2 | 3.2 | – | – | – | – | – | 91; GCA-GTA (Ala-Val) | – | – |
| Guizhou | New | M | 18 | MB | – | LL | Y | N | N | 3.7 | UT | UT | – | 55; CCC-TCC (Pro-Ser) | – | – | – | – | – | – |
| Guizhou | Relapse | F | 70 | MB | MDT | LL | Y | N | N | 4.2 | UT | UT | – | 55; CCC-CGC (Pro-Arg) | – | – | – | 91; GCA-GTA (Ala-Val) | – | – |
| Guizhou | Relapse | M | 61 | MB | MDT | BL | Y | N | N | 2.2 | 1.0 | 0.7 | – | – | – | 410; GAT-TAT (Asp-Tyr) | – | 91; GCA-GTA (Ala-Val) | – | – |
| Yunnan | New | M | 85 | MB | – | BL | Y | N | N | 3.2 | 0 | 0 | – | 55; CCC-TCC (Pro-Ser) | – | – | – | – | – | – |
| Yunnan | Relapse | M | 45 | MB | DDS mono | LL | Y | Y | N | 4.0 | 2.0 | 2.2 | – | 53; ACC-ATC (Thr-Ile) | – | – | – | – | – | – |
| Yunnan | New | F | 25 | MB | – | LL | Y | N | N | 3.5 | UT | UT | – | – | – | – | – | 91; GCA-GTA (Ala-Val) | – | A2143C |
| Guizhou | New | M | 41 | MB | – | BT | Y | N | Y | 1.5 | 0 | 0 | – | – | – | – | 698; AAC- ACC (Asp–Thr) | – | – | |
| Yunnan | New | M | 45 | MB | – | BL | N | N | N | 3.4 | UT | UT | – | – | – | – | – | 362; GGA- GAT (Gly–Asp) | – | |
| Yunnan | New | M | 35 | MB | – | BL | Y | N | Y | 3 | 3 | 3 | – | – | – | – | – | 362; GGA- GAT (Gly-Asp) | – | |
| Yunnan | Relapse | M | 78 | MB | MDT | BL | Y | N | N | 3.4 | 3.6 | 3.6 | – | – | – | – | – | 362; GGA- GAT (Gly–Asp) | – | |
| Yunnan | New | M | 79 | MB | – | BT | Y | N | Y | 0.2 | 0 | 0 | – | – | – | – | – | 362; GGA- GAT (Gly–Asp) | – | |
| Yunnan | New | F | 26 | MB | – | BL | Y | N | N | 3.6 | 3.6 | 3.6 | – | – | – | – | – | – | 214; GTG- GGG (Val– Gly) | |
| Hunan | Relapse | M | 72 | MB | MDT | LL | Y | Y | N | 4.2 | 3.2 | 3.2 | – | – | – | – | – | – | – | A2142C |
No shaded, fully shaded, and light-shaded indicates mutations in WHO-recommended, both WHO and extended, and extended DRDRs genes respectively, M-male, F-female, Y-yes, N-no, UT-under treatment.